• Tue. Oct 20th, 2020

Dimancherouge

Technology

Biotherapeutics

  • Home
  • A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of Its Potentially Transformative Selective Tumor Cell Therapeutics

A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of Its Potentially Transformative Selective Tumor Cell Therapeutics

A2 Biotherapeutics (www.a2bio.com), a biotechnology company developing innovative cell therapies for solid tumor cancer patients, today announced the closing of its $71.5M Series B financing. Proceeds will fund the advancement…